SCHEMBL20031290

SCHEMBL20031290

CN(C)Cc1cccc(-c2ccncc2)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.61
PRMT6 Q96LA8 1/20 0.60
ABHD6 Q9BV23 2/20 0.56
MGLL Q99685 1/20 0.53
TAAR1 Q96RJ0 2/20 0.51
HTR7 P34969 1/20 0.50
CHRNB2 P17787 1/20 0.50
CHRNA4 P43681 1/20 0.50
HRH3 Q9Y5N1 2/20 0.49
KIF11 P52732 1/20 0.47
ATP4A P20648 2/20 0.47
ATP4B P51164 2/20 0.47
AOC3 Q16853 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
MAPK14 Q16539 1/20 0.45
USP30 Q70CQ3 1/20 0.45
NOTUM Q6P988 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29864624 0.85 TAAR1 (0.67) ABHD6TAAR1HTR7HRH3AOC3
SCHEMBL3464184 0.85 TAAR1 (0.67) ABHD6TAAR1HTR7HRH3AOC3
SCHEMBL15263998 0.81 ABHD6 (0.69) PRKCIPRMT6ABHD6MGLLAOC3
SCHEMBL3245741 0.80 PRKCI (0.50) PRKCIPRMT6ABHD6MGLLTAAR1
SCHEMBL17276540 0.80 ABHD6 (0.64) PRKCIPRMT6ABHD6MGLLAOC3
SCHEMBL10066929 0.79 PRKCI (0.67) PRKCIPRMT6ABHD6HRH3KIF11
SCHEMBL27619110 0.79 HRH3 (0.74) TAAR1CHRNB2CHRNA4HRH3KIF11
SCHEMBL28128520 0.79 ABHD6 (0.53) PRKCIPRMT6ABHD6MGLLHRH3
SCHEMBL3140283 0.79 TAAR1 (0.51) PRMT6TAAR1HTR7HRH3ATP4A
SCHEMBL19496621 0.79 TAAR1 (0.70) TAAR1HTR7HRH3AOC3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11014912-B2 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-05-25 US disclosed
EP-3519385-B1 CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
WO-2018060689-A1 CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11014912-B2 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 USP30, USP39, USP28 PRKCI 981/4885PRMT6 792/4885ABHD6 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.